norepinephrine + terlipressin

Norepinephrine + terlipressin is a combination of two vasoactive agents used primarily in the management of severe circulatory failure, such as septic shock and hepatorenal syndrome (HRS). Norepinephrine (also known as noradrenaline) is a potent alpha-adrenergic agonist that acts as a vasopressor to increase vascular tone and blood pressure. Terlipressin is a synthetic vasopressin analog that acts mainly on V1a receptors, causing splanchnic and systemic vasoconstriction. The combination has been studied for its potential to improve hemodynamic stability, cardiac output, and renal perfusion in critically ill patients who do not adequately respond to monotherapy with either agent. Clinical studies suggest this combination may offer benefits such as improved cardiac output and central venous pressure in septic shock[1][3], and potentially higher rates of HRS resolution with fewer adverse effects compared to escalating doses of single agents[2]. However, risks include increased incidence of peripheral ischemia.

Other names

noradrenaline + terlipressin